Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow‐Up

We characterized the association between tumor size kinetics and survival in patients with advanced urothelial carcinoma treated with atezolizumab (anti‐programmed death‐ligand 1, Tecentriq) using a joint model. The model, developed on data from 309 patients of a phase II clinical trial, identified...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacology and therapeutics 2019-10, Vol.106 (4), p.810-820
Hauptverfasser:	Tardivon, Coralie, Desmée, Solène, Kerioui, Marion, Bruno, René, Wu, Benjamin, Mentré, France, Mercier, François, Guedj, Jérémie
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - pharmacokinetics Antineoplastic Agents, Immunological - pharmacokinetics B7-H1 Antigen - antagonists & inhibitors Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - mortality Carcinoma, Transitional Cell - pathology Clinical Decision Rules Clinical Trials as Topic Female Humans Male Middle Aged Prognosis Risk Assessment - methods Survival Analysis Tumor Burden Urologic Neoplasms - drug therapy Urologic Neoplasms - mortality Urologic Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!